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SUMMARY
Objective: Human anti-tumor necrosis factor (TNF-α) monoclonal antibody (infliximab) is used to treat au-
toimmune diseases such as rheumatoid arthritis (RA). Although the risk of worsening heart failure has been 
described in patients under chronic treatment, the acute cardiovascular effects of this drug are unknown in RA 
patients without heart failure. Methods: 14 RA patients with normal echocardiography and no history of heart 
failure were evaluated during the 2-hour infliximab (3-5 mg/kg) infusion period, using a noninvasive hemody-
namic beat-to-beat system (Portapres). Stroke volume (SV); systolic, diastolic and mean blood pressures (SBP, 
DBP and MBP, respectively); cardiac output (CO); heart rate (HR); and total peripheral vascular resistance 
(PVR) were recorded. All patients also received saline infusion instead of infliximab as a control. Significant 
differences in hemodynamic parameters were determined using Tuckey’s test. All values were expressed as mean 
± standard deviation (SD). Results: Fourteen RA patients (6M/8F) with mean age of 47.2 ± 8.8 years were evalu-
ated. A significant decrease was found in cardiac output and stroke volume (7.04 ± 2.3 to 6.12 ± 2.1 l/min and 
91 ± 29.0 to 83 ± 28.8 mL/beat, respectively) after infliximab infusion. Although not statistically significant, a 
progressive increase was detected in SBP, DBP and total PVR during infusion. Saline infusion did not cause 
significant hemodynamic changes in the same group of RA patients. No adverse effects were observed during 
the infusion period. Conclusion: Acute infliximab administration decreased cardiac output due to low stroke 
volume in RA patients without heart disease. The results also demonstrated that, in spite of its negative inotropic 
effect, infliximab enhanced BP, probably by increasing PVR. 
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RESUMO
Inﬂiximabe reduz débito cardíaco em pacientes com artrite  
reumatoide sem insuﬁciência cardíaca
Objetivo: O inibidor de fator de necrose tumoral (TNF-α) infliximabe é usado no tratamento de doenças au-
toimunes como a artrite reumatoide (AR). Embora o risco de piora de insuficiência cardíaca em pacientes sub-
metidos a tratamento crônico tenha sido descrito, os efeitos cardiovasculares agudos da infusão desta droga 
em pacientes com AR sem insuficiência cardíaca são desconhecidos. Métodos: Pacientes com AR e ecocar-
diogramas normais e sem antecedentes de insuficiência cardíaca foram avaliados durante o período de infusão 
de infliximabe (3-5mg/kg), de 2 horas, utilizando um sistema de monitoramento hemodinâmico não invasivo 
batimento-a-batimento (Portapres). As variáveis avaliadas foram: volume sistólico (VS), pressão arterial sistó-
lica, diastólica e média (PAS, PAD e PAM, respectivamente), débito cardíaco (DC), frequência cardíaca (FC) e 
resistência vascular periférica total (RVPT). Todos os voluntários também receberam infusão de soro fisiológico 
(SF) como estudo controle. Estatísticas foram avaliadas usando o teste de Tuckey. Os valores estão expressos em 
média ± desvio-padrão. Resultados: Catorze pacientes (6M/8F), com idade média de 47,2 ± 8,8 anos, foram 
avaliados. Reduções significativas no débito cardíaco e volume sistólico foram encontradas após a infusão do 
infliximabe (7,04 ± 2,3 a 6,12 ± 2,1 L/min e 91 ± 29,0 a 83 ± 28,8 mL/batimento, respectivamente). Embora não 
estatisticamente significante, detectaram-se aumentos progressivos na PAS, PAD e RVPT durante a infusão. A 
infusão controle de SF não causou mudanças hemodinâmicas significativas nos pacientes estudados. Não foram 
observados efeitos adversos no período de infusão. Conclusão: A administração de infliximabe reduz aguda-
mente o débito cardíaco devido a redução no volume sistólico em pacientes com AR sem insuficiência cardíaca. 
Nossos resultados mostram que, apesar do efeito inotrópico negativo, o infliximabe elevou a pressão arterial, 
provavelmente devido ao aumento na RVPT.
Unitermos: Infliximabe; inibidores de TNF-α; doenças autoimunes; artrite reumatoide; insuficiência cardíaca.
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INTRODUCTION
Affecting men and women, rheumatoid arthritis (RA) is 
an autoimmune disease of unknown etiology, whose prev-
alence increases with age. It primarily affects distal joints, 
causing destruction and deformation due to bone and car-
tilage erosion. In addition to joints, it affects other sites, 
such as the lungs and heart.
Over the last decade, the use of some antirheumatic 
drugs (DMARDs) has changed the disease course; partic-
ularly, methotrexate (MTX) and corticosteroids have dra-
matically enhanced the success of RA management1,2. In 
addition, the use of tumor necrosis factor-alpha (TNF-α) 
inhibitors was a major breakthrough in RA treatment.
Cardiovascular diseases are associated with increased 
inflammatory activity in RA, and this fact may be related 
to increased risk of heart failure3. TNF-α is an inflamma-
tory cytokine present in RA and is also related to cardiac 
injury through a variety of biological mechanisms, thus 
contributing to the progression of heart failure3. Although 
TNF-α inhibitors represent a major advance in the treat-
ment of rheumatic disease, their impact on cardiovascular 
risk in RA is unknown. These observations led to several 
large randomized controlled trials designed to assess the 
efficacy of TNF-α inhibitor therapy in the treatment of 
heart failure. Unfortunately, these efforts were unsuccess-
ful, since such trials were stopped prematurely due to lack 
of efficacy and worsening of heart failure in the groups 
treated with anti-TNF-α3-5.
Thus, although some useful insights were offered, 
there are still several unanswered questions regarding the 
safety of anti-TNF-α use6. For example, it is still unknown 
whether TNF-α inhibitor infusion causes acute cardiovas-
cular effects in RA patients without cardiac diseases.
METHODS
PATIENT POPULATION
RA patients followed in the Rheumatology Outpatient 
Clinic at the Teaching Hospital of the Universidade de 
Campinas with RA refractory to the usual treatment, ac-
cording to the Brazilian Consensus for the Diagnosis and 
Treatment of Rheumatoid Arthritis7 as well as the Ameri-
can College of Rheumatology/European League Against 
Rheumatism classification criteria8, participated in a pro-
tocol using the TNF-α inhibitor infliximab (Remicade®, 
Merck & Co – United States). Fourteen patients following 
treatment with methotrexate 12.5mg to 20mg/week and at 
least one conventional DMARD were included in the pres-
ent study. Eight of them were also using corticosteroids. At 
the time of the study, each patient had received at least four 
cycles of infliximab infusion.
All individuals completed a medical history ques-
tionnaire, and were submitted to physical examinations, 
electrocardiography, echocardiography, and biochemical 
tests. Patients with signs and symptoms of heart failure 
and abnormal echocardiogram9 were excluded. In addi-
tion, patients with impaired renal function, ischemic heart 
disease, liver disease, stroke, peripheral vascular disease, 
dyslipidemia, diabetes, or any other major diseases, as 
well as smokers, were also excluded. All subjects signed 
an informed consent, and the study was approved by the 
university’s ethics committee.
STUDY DESIGN
This study comprised 14 patients with RA. Data collection 
was performed before, during, and after a 3-5 mg/kg inflix-
imab dose was intravenously administered to each patient 
over a two-hour period. During this time, the calm, com-
fortably seated patients were monitored by a noninvasive 
system for hemodynamic evaluation, 15 minutes before 
and 15 minutes after infusion, and by office blood pressure 
(BP) measurements. After infusion, patients underwent a 
two-hour observation period, and were then discharged.
Two weeks after this first protocol, all 14 patients re-
ceived a saline intravenous infusion (500 mL) for two 
hours, and hemodynamic measurements were obtained 
as a control.
OFFICE BLOOD PRESSURE
Clinical values of BP were obtained three times from each 
patient, using a digital monitor (HEM-907 XL OMRON)10. 
While measuring BP, the participant remained seated with 
the arm comfortably placed at heart level11. BP was con-
sidered the mean of the two readings. Pulse pressure (PP) 
was calculated as: systolic BP (SBP) - diastolic BP (DBP).
HEMODYNAMIC ASSESSMENT (PORTAPRES SYSTEM)
The Portapres system (Finapres Medical Systems B.V. 
– Amsterdam, the Netherlands) was used for hemody-
namic monitoring4,12-14. Two cuffs were positioned on 
the middle phalanx of the third and fourth fingers, with 
the device alternating fingers every 30 min; the hand to 
which the measurement unit was applied was held in a 
constant position. The device measured hemodynamic 
parameters in real-time (beat-to-beat), including: heart 
rate (HR), the number of heartbeats per minute; SBP; and 
DBP. Portapres also registered the arterial pressure wave, 
comparing it with a database of more than 2,000 waves 
and then estimating: stroke volume (SV), the volume of 
blood ejected from the left ventricle with each beat; car-
diac output (CO), the volume of blood pumped by the 
heart in an one minute interval (CO = SV x HR); mean 
blood pressure (MBP); and total peripheral vascular re-
sistance (PVR), the sum of the resistance of peripheral 
vasculature in the systemic circulation. Thus, it provided 
a complete hemodynamic assessment of the cardiovascu-
lar system using a noninvasive method.
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DISEASE ACTIVITY
Disease activity was measured using two parameters: a 
functional disability questionnaire known as Health As-
sessment Questionnaire (HAQ)15,16 and the disease activity 
score (DAS 28), as well as certain routine inflammatory 
markers such as c-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR). The anti-cyclic citrullinated 
peptide usually used for RA diagnosis was not performed 
in this study8.
STATISTICAL ANALYSIS
The Statistical Analysis System, version 8.02 (SAS Institute 
Inc. – Cary, NC, USA), was used for all statistical analy-
ses. Normal distribution was assessed by the Kolmogorov-
Smirnov test. Significant hemodynamic differences during 
the protocol were determined using Tuckey’s test. A p-val-
ue < 0.05 indicated significance. All values were expressed 
as mean ± standard deviation (SD).
RESULTS
The general characteristics of the patients are listed in Ta-
ble 1. Baseline echocardiographic findings are shown in 
Table 2. The mean age of RA was 47.2 ± 8.8 years; women 
comprised 57% of the patients, and biochemical test re-
sults were normal. The mean left ventricle ejection frac-
tion was 70.3 ± 4.3%.
Disease activity variables are also shown in Table 1, in-
cluding rheumatoid factor levels at the time of treatment 
evaluation.
A significant decrease in cardiac output and stroke 
volume was observed after two-hour infliximab infusion 
(7.04 ± 2.3 to 6.12 ± 2.1 L/min and 91± 29.0 to 83 ± 28.8 
mL/beat, respectively). Conversely, SBP, DBP, and PVR 
progressively increased during infliximab infusion. These 
hemodynamic findings were normalized to each individu-
al body surface area and are expressed in Graphic 1. 
No symptoms were reported during the TNF-α inhibi-
tor administration. 
No hemodynamic changes were observed during sa-
line infusion protocol in the same RA patients. Results are 
shown in Table 3.
DISCUSSION 
The present study demonstrated that cardiac index and 
stroke volume index progressively decreased during inf-
liximab infusion in individuals not presenting clinical and 
echocardiographic evidences of heart failure and follow-
ing chronic treatment for rheumatoid arthritis. In healthy 
subjects, but not in RA patients, the normal cardiac re-
sponse for saline infusion should be an increase in stroke 
volume and cardiac output of approximately 10%, without 
significant change in heart rate or blood pressure17. These 
results found could not be due to other drugs taken by 
Clinical data RA (n = 14)
Age (years) 47.2 ± 8.8
BMI (kg/m2) 27.6 ± 1.3
Gender M/F 6/8
RA duration (years) 10.9 ± 4.4
Blood pressure
Ofﬁce SBP (mmHg) 121.0 ± 10.9
Ofﬁce DBP (mmHg) 78.1 ± 10.7
Laboratory parameters
Glycemia (mg/dL) 78.6 ± 17.0
Total cholesterol (mg/dL) 174.1 ± 20.5
LDL cholesterol (mg/dL) 89.3 ± 16.7
Triglycerides (mg/dL) 141.8 ± 58.7
Potassium (mEq/L) 4.1 ± 0.7
Creatinine (mg/dL) 1.0 ± 0.1
AST (mg/dL) 20 ± 3.4
ALT (mg/dL) 20 ± 10
DAS
DAS 28 4.3 ± 2.0
HAQ 11.4 ± 3.6
Inﬂammatory markers
CRP 2.4 ± 1.8
ESR 31.9 ± 18.6
Rheumatoid factor +/- 10/4
RA, rheumatoid arthritis; n, number of patients; BMI, body mass 
index; M/F, male/female; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; LDL, low-density lipoproteins; AST, aspartate 
transaminase; ALT, alanine transaminase; DAS, Disease Activity 
Score; HAQ, Health Assessment Questionnaire; CRP, c-reactive 
protein; ESR, erythrocyte sedimentation rate. Values are expressed 
as means ± SD.
Table 1 – General characteristics of patients with rheumatoid 
arthritis
RA (n = 14)
Aorta (mm) 28.1 ± 2.0
LA (mm) 36.6 ± 2.7
LV septal thickness (mm) 9.5 ± 0.5
LV posterior wall thickness (mm) 9.1 ± 1.1
LV end-diastolic diameter (mm) 50.8 ± 3.0
LV end-systolic diameter (mm) 31.9 ± 2.8
Ejection fraction (%) 70.3 ± 4.3
LV mass/BSA (g/m2) 96.0 ± 9.2
RA, rheumatoid arthritis; LA, left atrium; LV, left ventricle; BSA, body 
surface area. Values are expressed as means ± SD.
Table 2 – Pre-study transthoracic echocardiography 
parameters in RA patients
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patients, since infliximab was the only new treatment ad-
ministrated during the study. Also, there are no reports of 
cardiac injury caused by infliximab synergism with other 
drugs. Therefore, only a direct effect of infliximab on the 
heart could be responsible for the impairment in cardiac 
output in these patients. Inversely to healthy individuals17, 
SPB and total PVR increased during the TNF-α inhibitor 
administration. To the authors’ knowledge, this is the first 
time that hemodynamic parameters have been evaluated 
in RA patients during acute infusion of infliximab in order 
to better evaluate its impact on cardiovascular function. 
It is noteworthy that hemodynamic measurements were 
obtained by using the Portapres system, which has a near-
zero bias (7% error) when compared with gold standard 
invasive methods such as triplicate thermodilution. It is 
probable that the two large randomized trials that stud-
ied anti-TNF-α infusion in heart failure patients did not 
detect cardiovascular effects because low doses of inflix-
imab were administrated, and hemodynamic parameters 
were not monitored by an accurate method such as the 
Portapres system. Using this system, the present find-
ings demonstrated that, even using moderate infliximab 
doses, its acute infusion may cause asymptomatic cardiac 
dysfunction.
It is known that the main cause of death in RA is car-
diovascular disease (CVD)18, and the overall increase 
in heart failure among RA patients may be related to in-
creased inflammatory activity, perhaps leading to prema-
ture atherosclerosis. In fact, clinical markers of inflamma-
tion have been associated with cardiovascular mortality 
and morbidity in RA patients5. Contrarily to the healthy 
cardiac tissue, heart failure is of special interest because 
the failing heart produces TNF19. Inversely to the lack of 
data regarding the effects of circulating TNF-α on cardio-
vascular function in humans19-22, studies in mice using 
heart failure models suggest improvement in ventricular 
dysfunction by circulating TNF blockade23,24. However, 
these results could not be reproduced in patients, and on 
the contrary, clinical trials showed that patients with heart 
failure had no benefit from the anti-TNF-α drug use, and 
it could even make their disease worse. These large ran-
domized trials confirmed that patients with heart failure 
NYHA class III-IV had disease progression associated 
with infusion of high doses of anti-TNF-α (10mg/kg). 
Nevertheless, the safety of patients without heart failure is 
still uncertain21,25.
Several pathophysiologic mechanisms contribute to 
cardiac injury, especially elevated oxidative stress and in-
flammation, which correlate with a variety of conditions 
such as hypertension, coronary artery disease, cardiomy-
opathy, atherosclerosis, and heart failure26. TNF-α is the 
most important cytokine related to these mechanisms. 
Increased TNF-α levels in inflammatory states lead to a 
high concentration of reactive oxygen species (ROS), in a 
vicious cycle, causing elevation of pro-oxidants. The im-
balance between pro-oxidants and antioxidants causes 
systemic injury, including heart failure by DNA damage, 
protein nitration, lipid peroxidation, and activation of ma-
trix metalloproteinases27,28. 
Conversely, despite the fact that TNF-α inhibition 
can both preserve cardiac function and partially reverse 
pathological changes in congestive heart failure24 in ani-
mal models, this could not be reproduced in humans. Such 
RA (n=14) Before saline After saline 
SBP (mmHg) 163 ± 13 161 ± 15
DBP (mmHg) 86.7 ± 8.2 88.3 ± 3.1
Heart rate (bpm) 74.3 ± 17.0 74.67 ± 11.7
Stroke volume (mL) 80.5 ± 16.9 80.9 ± 24.4
Cardiac output (L/min) 6.1 ± 2.7 6.2 ± 2.9
Peripheral vascular 
resistance  
(dina.sec.cm-5)
1,701 ± 708.9 1,771 ± 718.4
RA, rheumatoid arthritis; n, number of patients; SBP, systolic blood 
pressure; DBP, diastolic blood pressure. Values are expressed as 
means ± standard deviation.
Table 3 – Control group hemodynamic parameters
Graphic 1 – Hemodynamic changes during 2-hour inﬂiximab 
infusion (3-5 mg/kg) in RA patients (n = 14). *p < 0.001 
versus before infusion. #p < 0.05 versus 60 minutes. SBP, 
systolic blood pressure; DBP, diastolic blood pressure, PVR, 
peripheral vascular resistance.
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difficulty has probably occurred because mice heart failure 
models were transgenic (TNF1.6) with cardiac-specific 
overexpression of TNF-α, and heart failure in humans 
has several enrolled cytokines and ROS due to inflamma-
tion. The question “why is TNF-α inhibition harmful?” 
remains answered. According to some authors, infliximab 
can cause cell lyses in the presence of a complement29, as 
well as a rebound effect of TNF-α toxicity on infliximab 
infusion22. Since the actual cause is not known, there is no 
evidence regarding the safe dose of infliximab.  
Some relevant aspects should be highlighted when ana-
lyzing these results, because a number of potential limita-
tions must be considered. First, a small number of RA pa-
tients were enrolled in the study. However, even studying 
a small sample of subjects, the Portapres system allows for 
continuous recording (beat-to-beat) of hemodynamic vari-
ables; the standard errors of means were very small and a 
test power of 0.72 was achieved. Second, patients did not 
have a long-term follow-up, so the accumulative dose effects 
of infliximab on cardiac function could not be analyzed. 
And finally, due to the small sample of patients studied, 
there was no standardization of RA duration and severity.  
The present findings suggest that a two-hour infliximab 
infusion decreases cardiac output and stroke volume, even 
in RA patients without clinical and echocardiographic 
evidences of previous cardiac dysfunction. The results also 
demonstrate that, in spite of its possible negative inotropic 
effect, infliximab may enhance BP, probably by increasing 
PVR. However, considering the limitations of this study 
and of others, further investigations on acute and long-
term administration of this anti-TNF-α drug, involving a 
higher number of subjects, should be performed in order 
to assess the safety of this RA treatment.
ACKNOWLEDGEMENTS
This study was supported by the Fundação de Amparo à 
Pesquisa do Estado de São Paulo (Fapesp), by the Conse-
lho Nacional de Desenvolvimento Científico e Tecnológi-
co (CNPq), and by the Coordenação de Aperfeiçoamento 
de Pessoal de Nível Superior (Capes), Brazil.
REFERENCES
1. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for 
treatment of rheumatoid arthritis. Lancet. 2007;370:1861-74.
2. Doan T, Massarotti E. Rheumatoid arthritis: an overview of new and emerging 
therapies. J Clin Pharmacol. 2005;45:751-62.
3. Mann DL. Inflammatory mediators and the failing heart: past, present, and the 
foreseeable future. Circ Res. 2002;91:988-98.
4. Lysander WJ, Van Lieshout JJ. Non-invasive pulsatile arterial pressure and 
stroke volume changes from the human finger. Exp Physiol. 2005;90:437-46.
5. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent 
of inflammation predicts cardiovascular disease and overall mortality in sero-
positive rheumatoid arthritis. A retrospective cohort study from disease onset. 
J Rheumatol. 1999;26:2562-71.
6. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime 
adverse drug reactions, service utilization, and disease severity among patients 
who will start COX-2 specific inhibitors: quantitative assessment of channeling 
bias and confounding by indication in 6689 patients with rheumatoid arthritis 
and osteoarthritis. J Rheumatol. 2002;29:1015-22.
7. Bértolo MB, Brenol CV, Schainberg CG, Neubarth F, Lima FAC, Laurindo IM, 
et al. Atualização do consenso brasileiro no diagnóstico e tratamento da artrite 
reumatóide. Rev Bras Reumatol. 2007;47:151-9.
8. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et 
al. 2010 rheumatoid arthritis classification criteria: an American College of 
Rheumatology/European League Against Rheumatism collaborative initiative. 
Arthritis Rheum. 2010;62:2569-81.
9. Lang EA. Recommendations for chamber quantification: a report from the 
American Society of Echocardiography’s Guidelines and Standards Commit-
tee and the Chamber Quantification Writing Group. J Am Soc Echocardiogr. 
2005;18:1440-63.
10. El Assaad MA, Topouchian JA, Darne BM, Asmar RG. Validation of the Om-
ron HEM-907 device for blood pressure measurement. Blood Press Monit. 
2002;7:237-41.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et 
al. The Seventh report of the Joint National Committee on Prevention, Detec-
tion, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. 
JAMA. 2003;289:2560-72.
12. Langewouters GJ, Settels JJ, Roelandt R, Wesseling KH. Why use Finapres or 
Portapres rather than intra-arterial or intermittent non-invasive techniques of 
blood pressure measuremant?. J Med Eng Technol. 1998;22:37-43.
13. Jansen JRC, Schreuder JJ, Mulier JP, Smith NT, Settels JJ, Wesseling KH. A 
comparison of cardiac output derived from the arterial pressure wave against 
thermodilution in cardiac surgery patients. Br J Anaesth. 2001;87:212-22.
14. Leonetti P, Audat F, Girard A, Laude D, Lefrère F, Elghozi J. Stroke volume 
monitored by modeling flow from finger arterial pressure waves mirrors blood 
volume withdrawn by phlebotomy. Clin Auton Res. 2004;14:176-81.
15. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: 
status and review. Arthritis Care Res. 1992;5:119-29.
16. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis 
Rheum. 2000;43:2751-61.
17. Kumar A, Anel R, Bunnell E, Habet K, Neumann A, Wolff D, et al. Effect of 
large volume infusion on left ventricular volumes, performance and contractil-
ity parameters in normal volunteers. Intensive Care Med. 2004;30:1361-9.
18. Ku IA, Imboden JB, Hsue PY, Ganz P. Rheumatoid arthritis: model of systemic 
inflammation driving atherosclerosis. Circ J. 2009;73:977-85.
19. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Ef-
ficacy and safety of adalimumab as monotherapy in patients with rheumatoid 
arthritis for whom previous disease modifying antirheumatic drug treatment 
has failed. Ann Rheum Dis. 2004;63:508-16.
20. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Bir-
bara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha 
monoclonal antibody, for the treatment of rheumatoid arthritis in patients 
taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 
2003;48:35-45.
21. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. 
Targeted anticytokine therapy in patients with chronic heart failure: results of 
the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 
2004;109:1594-602.
22. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, dou-
ble-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal 
antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe 
heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure 
(ATTACH) trial. Circulation. 2003;107:3133-40.
23. Kubota T, Bounoutas GS, Miyagishima M, Kadokami T, Sanders VJ, Bruton C, 
et al. Soluble tumor necrosis factor receptor abrogates myocardial inflamma-
tion but not hypertrophy in cytokine-induced cardiomyopathy. Circulation. 
2000;101:2518-25.
24. Kadokami T, Frye C, Lemster B, Wagner CL, Feldman AM, McTiernan CF. 
Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic 
model. Circulation. 2001;104:1094-7.
25. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, et 
al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in 
an observational cohort study: comparison of patients according to their eligi-
bility for major randomized clinical trials. Arthritis Rheum. 2006;54:3399-407.
26. Khaper N, Bryan S, Dhingra S, Singal R, Bajaj A, Pathak CM, et al. Targeting 
the vicious inflammation-oxidative stress cycle for the management of heart 
failure. Antioxid Redox Signal. 2010;13:1033-49.
27. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 
2005;115:500-8.
28. Matsuzawa A, Ichijo H. Redox control of cell fate by MAP kinase: physiological 
roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta. 
2008;1780:1325-36.
29. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-
alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-
alpha and activates immune effector functions. Cytokine. 1995;7:251-9.
